Clinical Efficacy of Xuanfei Huazhuo Prescription on 40 Cases of COVID-19
10.13422/j.cnki.syfjx.20201704
- VernacularTitle:宣肺化浊加减方治疗新型冠状病毒肺炎40例临床疗效观察
- Author:
Tong-fan SHI
1
;
Gu-cheng ZHOU
1
;
Li-ying ZHANG
1
;
Fan NIU
2
;
Yi-cheng KE
1
;
Ting ZHOU
1
;
Qing-sheng WANG
2
;
Xiao-jie JIN
1
;
Dong-ling LIU
1
;
Ben-jun WEI
1
;
Wei-qiang ZHANG
2
;
Zhi-ming ZHANG
2
;
Yong-qi LIU
1
Author Information
1. Dunhuang Key Laboratory of Medical Transformation Co-constructed by Ministry of Education and Gansu Province,Gansu Provincial Key Laboratory for Molecular Medicine of Major Diseases and Study on Prevention and Treatment with Traditional Chinese Medicine for Colleges and Universities,| Gansu University of Chinese Medicine,Lanzhou 730000,China
2. Affiliated Hospital of Gansu University of Chinese Medicine,Lanzhou 730000,China
- Publication Type:Research Article
- Keywords:
Xuanfei Huazhuo prescription;
coronavirus disease-2019 (COVID-19);
symptom;
treatment with traditional Chinese medicine;
efficacy
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2020;26(16):26-31
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the clinical efficacy of Xuanfei Huazhuo prescription in the treatment of coronavirus disease-2019 (COVID-19). Method:A total of 40 patients with COVID-19 were selected and treated with Xuanfei Huazhuo prescription. The changes of body temperature, clinical symptoms, computed tomography (CT), blood routine and biochemical indexes were observed before and after treatment. Result:The 40 patients included 15 males and 25 females, with a male to female ratio of 1∶1.7. They were aged between 20-94 years old, with the average age of （43.9±16.3） years old. The course of disease was 8-23 days, with the average of （14±4.4） days. Compared with before administration, the patients' clinical symptoms, such as cough, fever, sputum, diarrhea, loss of appetite and fatigue, were all improved (P<0.05). Before treatment the traditional Chinese medicine (TCM) syndromes of patients were mainly cold dampness lung (57.5%) and cold dampness Lung (42.5%), and the tongue coating was mainly white greasy coating (52.9%). After adjuvant treatment with Xuanfei Huazhuo prescription, the fever removal time was (2.48±2.56) days; white blood cell (WBC), lymphocyte percentage (LYM%), neutrophil percentage (NEUT%), absolute value of lymphocytes (LYM #) indexes of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), total bilirubin (TBIL), ratio of glutamic oxaloacetic transaminase to glutamic pyruvic transaminase (AST/ALT) and lactate dehydrogenase (LDH) were basically restored to the normal range (P<0.05) compared with before administration. After adjuvant treatment with Xuanfei Huazhuo prescription, the results of three pharyngeal test virus nucleic acid tests were negative, and the lung CT showed that infected lesions were absorbed and all met the discharge criteria. All 40 patients met the discharge criteria and were all cured and discharged, with a cure rate of 100%. There has been no case of recurrence with a positive result of nucleic acid detection so far. The score of symptom and clinical index of patients after administration was （1.62±1.90）, which was significantly lower than that before administration (7.65±4.08, P<0.05). Conclusion:In the adjuvant treatment of COVID-19, Xuanfei Huazhuo prescription can reduce body temperature, promote the absorption of pulmonary inflammation, and improve clinical symptoms, such as fever and cough.
